cyclobenzaprine hydrochloride

(redirected from Amrix)
Also found in: Dictionary, Thesaurus.

cyclobenzaprine hydrochloride

Amrix, Apo-Cyclobenzaprine (CA), Dom-Cyclobenzaprine (CA), Fexmid, Flexeril, Novo-Cycloprine (CA) PHL-Cyclobenzaprine (CA), PMS-Cyclobenzaprine (CA), Ratio-Cyclobenzaprine (CA), Riva-Cyclobenzaprine (CA)

Pharmacologic class: Autonomic nervous system drug

Therapeutic class: Skeletal muscle relaxant (centrally acting)

Pregnancy risk category B


Unclear. Thought to act primarily at brain stem (and to a lesser extent at spinal cord level) to relieve skeletal muscle spasms of local origin without altering muscle function.


Capsules (extended-release): 15 mg, 30 mg

Tablets: 5 mg, 7.5 mg, 10 mg

Indications and dosages

Adjunct to rest and physical therapy to relieve muscle spasm associated with acute, painful musculoskeletal conditions

Adults: 5 mg P.O. t.i.d. (immediate-release tablet). May increase to 10 mg P.O. t.i.d. (immediate-release tablet) as needed. Or, 15 mg (extended-release capsule) P.O. daily; some patients may need up to 30 mg/day, given as one 30-mg (extended-release capsule) P.O. daily or two 15-mg (extended-release capsules) P.O. daily.


• Hypersensitivity to drug

• Acute recovery phase after myocardial infarction (MI)

• Heart failure

• Arrhythmias

• Hyperthyroidism

• MAO inhibitor use within past 14 days


Use cautiously in:

• cardiovascular disease, closed-angle glaucoma, hepatic impairment, increased intraocular pressure, urinary retention

• elderly patients

• pregnant or breastfeeding patients

• children younger than age 15.


Don't give within 14 days of MAO inhibitor. Drug interaction may cause hypertensive crisis and severe seizures.

• Give extended-release capsule at approximately the same time each day.

• Know that drug shouldn't be used for more than 3 weeks.

• Be aware that drug may not be first-line agent for elderly patients because of its anticholinergic effects.

Adverse reactions

CNS: dizziness, drowsiness, syncope, confusion, fatigue, headache, nervousness, decreased mental acuity, irritability, weakness, insomnia, depression, disorientation, delusions, peripheral neuropathy, abnormal gait, Bell's palsy, EEG changes, extrapyramidal symptoms, cerebrovascular accident

CV: vasodilation, tachycardia, chest pain, hypotension, MI, heart block

EENT: blurred vision

GI: nausea, constipation, dyspepsia, swollen parotid glands, mouth inflammation, discolored tongue, dry mouth, paralytic ileus

GU: galactorrhea, urinary retention, urinary frequency, gynecomastia, testicular swelling, libido changes, erectile dysfunction

Hematologic: purpura, eosinophilia, bone marrow depression, leukopenia, thrombocytopenia

Metabolic: hyperglycemia, hypoglycemia, syndrome of inappropriate diuretic hormone secretion

Musculoskeletal: muscle ache

Respiratory: dyspnea

Skin: photosensitization, alopecia, angioedema

Other: unpleasant taste, weight gain or loss, edema


Drug-drug. Anticholinergics, anti-cholinergic-like drugs (including anti-depressants, antihistamines, disopyramide, haloperidol, phenothiazines): additive anticholinergic effects

Antihistamines, CNS depressants, opioids, sedative-hypnotics: additive CNS depression

Guanadrel, guanethidine: reduction in or blockage of these drugs' actions

MAO inhibitors: hyperpyretic crisis, seizures, death

Drug-herbs. Chamomile, hops, kava, skullcap, valerian: increased CNS depression

Drug-behaviors. Alcohol use: increased CNS depression

Patient monitoring

• Assess for adverse CNS effects, such as drowsiness, dizziness, and decreased mental acuity.

• Monitor patient for evidence of drug interactions, especially when giving drug with CNS depressants.

Patient teaching

• Tell patient to take extended-release capsule at approximately the same time each day.

• Tell patient that drug may cause dry mouth.

• Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration, alertness, and vision.

• Advise patient not to use alcohol, sedatives, pain medications, over-the-counter preparations, or herbs without consulting prescriber.

• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, herbs, and behaviors mentioned above.

cyclobenzaprine hydrochloride

a muscle relaxant.
indication It is prescribed in the short-term treatment of muscle spasm.
contraindications Hyperthyroidism, cardiac arrhythmia, cardiac failure, concomitant use of a monoamine oxidase inhibitor, or known hypersensitivity to this drug prohibits its use. It is used with caution in conditions in which anticholinergics are contraindicated.
adverse effects The most serious adverse effects are hypersensitivity reactions. Drowsiness, dry mouth, and dizziness commonly occur.
Mentioned in ?
References in periodicals archive ?
AMRIX (Cyclobenzaprine Hydrochloride Extended-Release Capsules) is approved for use along with rest and physical therapy to help control muscle spasm associated with acute, painful musculoskeletal conditions, added Watson Pharmaceuticals Inc.
For the 12 months ending 31 March 2011, AMRIX had sales of about USD125m (EUR88.
Cyclobenzaprine HCl ER Capsules are the generic version of Cephalon's (NASDAQ: CEPH) Amrix Capsules, a muscle relaxant.
According to the company, Cyclobenzaprine HCl ER Capsules are the generic version of Cephalon's Amrix Capsules, a muscle relaxant.
Annual sales in the United States for Provigil and Amrix are around $1.
Strong anticipated sales of Zentase, in addition to the royalties on the sales of Cephalon's (Nasdaq: CEPH) Amrix and GlaxoSmithKline, Inc.
Reddy's (505(b)2) Alphagan P Allergan Exela Pharmsci/Paddock Alphagan P Allergan FDA web-sub 12/20/06 Amrix Cephalon Mylan Antara Oscient Lupin Argatroban Injection Encysive Barr Aricept Pfizer/Eisai Teva, Ranbaxy Arthrotec Pfizer Teva Asacol P&G Roxane Atripla Gilead Teva Axid oral sol.
s (Nasdaq: CEPH) Amrix and GlaxoSmithKline Plc's (NYSE: GSK) EUR-1048 will drive the company to profitability in 2009 and beyond.
With Provigil protected from the entry of generics until October 2011, we believe that investor focus will shift towards the company's emerging oncology pipeline and muscle relaxer Amrix.
Strong sales of Zentase coupled with the royalties on the sales of Cephalon's (Nasdaq: CEPH) Amrix and GlaxoSmithKline's (NYSE: GSK) EUR-1048 (launch by end 2008) will drive the company to profitability in 2009 and beyond.
Eurand's pipeline is robust with late-stage drug candidates for its partners including Amrix, which has been approved by the FDA and will be marketed by Cephalon (Nasdaq: CEPH).